title: Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease.
authors.forename: A
authors.initials: A
authors.lastname: Tsuboi
authors.forename: Y
authors.initials: Y
authors.lastname: Oka
authors.forename: T
authors.initials: T
authors.lastname: Kyo
authors.forename: Y
authors.initials: Y
authors.lastname: Katayama
authors.forename: O A
authors.initials: OA
authors.lastname: Elisseeva
authors.forename: M
authors.initials: M
authors.lastname: Kawakami
authors.forename: S
authors.initials: S
authors.lastname: Nishida
authors.forename: S
authors.initials: S
authors.lastname: Morimoto
authors.forename: A
authors.initials: A
authors.lastname: Murao
authors.forename: H
authors.initials: H
authors.lastname: Nakajima
authors.forename: N
authors.initials: N
authors.lastname: Hosen
authors.forename: Y
authors.initials: Y
authors.lastname: Oji
authors.forename: H
authors.initials: H
authors.lastname: Sugiyama
mesh_terms: D000328:Adult; D019496:Cancer Vaccines / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000276:immunology / Q000628:therapy*; D009842:Oligopeptides / Q000008:administration & dosage / Q000276:immunology*; D012074:Remission Induction; D013997:Time Factors; D014611:Vaccination
chemical_list: D019496:Cancer Vaccines; D009842:Oligopeptides